Anti-HIV ribozyme therapy (Johnson & Johnson)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAnti-HIV ribozyme therapy (Johnson & Johnson)
Drug Alias NameRRz-2OZ-1
ClassificationCell and gene therapy > Gene therapy
Mechanisms of ActionGene transference
TargetsNot applicable
Therapy Area/IndicationsHIV Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesUniversity Of CaliforniaJohnson & Johnson
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesUniversity Of CaliforniaJohnson & Johnson
Active IndicationsN/A
Inactive IndicationsHIV Infections

Other Information

ATC CodeN/A
Related LinksN/A